Skip to content

Clinical trials

Phase 3 Leukemia, Myeloid, Acute trials in China

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Leukemia, Myeloid, Acute Phase: Phase 3 Country / region: China Clear all

53 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20041
20101
20111
20121
20144
20161
20176
20181
20193
20203
20214
20224
20237
20248
20254
20264

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Recruiting15
Unknown status14
Completed12
Not yet recruiting5
Active, not recruiting4
Terminated2
Enrolling by invitation1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
The First Affiliated Hospital of Soochow University9
AbbVie4
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences3
Daiichi Sankyo2
Institute of Hematology & Blood Diseases Hospital, China2
Nanfang Hospital, Southern Medical University2
Shanghai Jiao Tong University School of Medicine2
The Second Affiliated Hospital of Kunming Medical University2
Apollomics Inc.1
Ascentage Pharma Group Inc.1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Leukemia, Myeloid, Acute53
Leukemia5
Myelodysplastic Syndromes4
Recurrence2
Graft vs Host Disease1
Leukemia, Myelomonocytic, Chronic1
Neoplasm Metastasis1
Neoplasms1
Thrombocytopenia1

Trials

Showing 1 to 25 of 53. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.